New website is here!
Create an account to use the new features. Feel free to leave us feedback, constructive criticism welcome!
APH's Principal Activity is the produces, manufactures and distributes a range of hemp products under the Australian Primary Hemp brand, to retail, wholesale and white label customers in Australia. APH engages across the hemp value chain, encompassing hemp seed selection, farming, processing, packaging as well as distribution and sale of bulk and retail products.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+193.20%|
|vs ASX 200 (1yr)||+193.38%|
|ASX Rank||1633 of 2,466|
|Sector Rank||60 of 75|
Australian Primary Hemp Limited (APH, formerly Alchemia Limited) is a producer, manufacturer and distributor of premium plan-based and wellness products. The Group operates in Australia and engages across the hemp value chain, encompassing hemp seed selection, farming, processing, packaging as well as distribution and sale of bulk and retail products.
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Neale Joseph||Chief Executive Officer, Managing Director||Mar 2020||
Mr Neale Joseph
Chief Executive Officer, Managing Director
Mr Joseph joined APH as Head of Product in January 2020. Neale has experience in FMCG, pharmacy, B2B distribution, procurement, and operations to the APH Board. In his previous CEO roles, Neale has led businesses across Australia, New Zealand, Asia Pacific, and the Middle East. Prior to joining APH, Neale co-founded a start-up in the natural health and beauty industry where he grew distribution to retailers in Australia, New Zealand, Canada, the United States, and Europe.
|Mr James Hood||Executive Director, Chief Operating Officer||Oct 2019||
Mr James Hood
Executive Director, Chief Operating Officer
Mr Hood have experience in production facility development and an network of farmers, which has positioned Australian Primary Hemp well to produce a complete vertically integrated product line. Prior to Australian Primary Hemp, Mr Hood had roles in agriculture, subsea engineering and digital software development.
|Ms Pauline Therese Gately||Non-Executive Director, Non-Executive Chairman||Oct 2019||
Ms Pauline Therese Gately
Non-Executive Director, Non-Executive Chairman
Ms Gately has experience across a range of portfolio of Board positions. Pauline brings a commercial focus to strategy and risk. She embraces dynamic business environments and has knowledge of navigating changing directional points. Her experience spans IPO through acquisitions and mergers. During her investment banking career, Pauline held senior positions with CitiBank, BNP International, Merrill Lynch, and Deutsche Bank. She served as a non-executive director and subsequently executive chairperson of Alliance Mineral Assets Limited (SGX: 40F) from 2011 through to December 2018. She is also member of Risk Committee.
|Mr Cameron Petricevic||Non-Executive Director||Jun 2018||
Mr Cameron Petricevic
Mr Petricevic has spent over 15 years in the financial industry, with roles at AXA Asia Pacific Holdings (now AMP) and Acorn Capital. Cameron has investment banking experience, including valuations, mergers and acquisitions, and portfolio management. Cameron is a director of Kentgrove Equity Partners Pty Ltd and several private businesses. Cameron is Founder/Treasurer of Brimbank ToRCH, a Royal Children's Hospital auxiliary charity. He is member of the Risk Committee.
|Dr Tracie Ramsdale||Non-Executive Director||May 2018||
Dr Tracie Ramsdale
Dr Ramsdale following a successful career as a Principal Investigator and Commercial Manager of the Centre for Drug Design and Development at the University of Queensland, Tracie co-founded Alchemia Limited, a drug discovery and development company and served as the company's CEO for almost 10 years. During this time, she was responsible for multiple financing transactions and licensing the company's technology to international pharmaceutical and manufacturing partners. Dr Ramsdale has served on a number of industry and government advisory groups and provided independent consulting advice to the biotechnology industry, academia and government. Tracie is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a Member of the Australian Institute of Company Directors.
|Ms Melanie Jaye Leydin||Chief Financial Officer, Company Secretary||Apr 2016||
Ms Melanie Jaye Leydin
Chief Financial Officer, Company Secretary
Ms Leydin graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and since February 2000 has been the principal of LeydinFreyer. The practice provides outsourced company secretarial and accounting services to public and private companies specialising in ASX listed entities. Melanie has over 25 years experience in the accounting profession and has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies and shareholder relations.
|Dr Melvyn John Bridges||Non-Executive Director||Sep 2015||
Dr Melvyn John Bridges
Dr Bridges has over 35 years experience founding and building international lifescience, diagnostic and medical device companies and commercialising a range of Australian technology. He is in charge for commercial and M&A transactions and liquidity events, including listings on the ASX. He has founded and had develop medical device and diagnostic companies, including Pacific Diagnostics (acquired by Baxter), PanBio Ltd (acquired by Inverness Medical). He was a director of Tissue Therapies Ltd (March 2009 to December 2015), Benitec BioPharma Limited (October 2007 to June 2014) and Anatara Lifesciences Ltd (until May 2018). He serves as a member of the Risk Management Committee.
|Mr David Lamm||Executive Chairman, Executive Director||Jul 2015||
Mr David Lamm
Executive Chairman, Executive Director
Mr Lamm has over 16 years of experience in business and financial markets including roles at Credit Suisse, Bain & Company and the Alter Family Office. He is the founder and Managing Director of Kentgrove Capital. He is the Chairman of Investment Committee.
APH directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|22/10/20||Pauline Gately||Issued||334,000||$0.18||$60,120||Issue of options|
|22/10/20||Cameron Petricevic||Issued||334,000||$0.18||$60,120||Issue of options|
|21/10/20||James Hood||Issued||2,280,000||$0.18||$410,400||Issue of securities|
|18/11/19||Charles Mann||Buy||+249,020||$0.201||$50,043||On-market trade|
|14/11/19||Charles Mann||Buy||+657||$0.18||$118||On-market trade|
|11/11/19||Charles Mann||Buy||+4,494||$0.18||$809||On-market trade|
|02/10/19||Cameron Petricevic||Issued||1,216,904||$0.011||$13,386||Issue of securities|
|02/10/19||Cameron Petricevic||Issued||4,196,500||$0.011||$46,162||Issue of securities|
The current holdings of APH directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
Data supplied by Morningstar and accurate on Aug 19, 2020.
It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.
All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).
|CIA Mann Family Pty Ltd||8,543,671||12.25%|
|HSBC Custody Nominees (Australia) Limited||5,499,786||7.88%|
|James Robert Hood Pty Ltd||5,320,000||7.63%|
|TTOR Pty Ltd||4,999,999||7.17%|
|Mutual Trust Pty Ltd||3,250,000||4.66%|
|Crofton Park Development Pty Ltd||2,736,667||3.92%|
|Jasforce Pty Ltd||2,350,000||3.37%|
|CG Nominees (Australia) Pty Ltd||2,000,000||2.87%|
|Shomron Pty Ltd||1,971,338||2.83%|
|Sem Patterson Pty Ltd||1,540,000||2.21%|
|LD Fifty Ltd||1,250,000||1.79%|
|Cassa Trading Pty Ltd||1,227,435||1.76%|
|Brittany Pty Ltd||1,100,000||1.58%|
|Mr Ashley James Hardwick||1,100,000||1.58%|
|Peter Johnson & Kim Johnson||1,100,000||1.58%|
|NA Investments (Vic) No 2 Pty Ltd||1,100,000||1.58%|
|Stepheno Holdings Pty Ltd||971,022||1.39%|
|Citicorp Nominees Pty Limited||671,106||0.96%|
|Kent Street Capital No. 2 Pty Ltd||650,000||0.93%|
|Okulicz Pty Ltd||640,661||0.92%|
|Holding Size||1 - 1,000||1,001 - 5,000||5,001 - 10,000||10,001 - 100,000||100,001+||Total|
|No. of Shareholders||3,367||564||191||268||64||4,454|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held under multiple names so the Substantial Shareholders list differs from the Top 20 Shareholders list.
|Name||Last Notice||Total Shares||Shares Held (%)|
|HSBC Custody Nominees (Australia) Limited||19/08/2020||5,499,786||7.88|
|TTOR Pty Ltd||19/08/2020||4,999,999||7.17|
|CIA Mann Family Pty Ltd||21/10/2020||11,550,000||15.14|
|James Robert Hood Pty Ltd||21/10/2020||7,600,000||9.96|
|Wexford Rise Pty Ltd||23/09/2020||4,525,000||6.52|
|Date||Name||Bought||Previous %||New %|
|21-10-20||James Robert Hood Pty Ltd||2,280,000||7.70||9.96|
|21-10-20||CIA Mann Family Pty Ltd||3,465,000||11.60||15.14|
|23-09-20||Wexford Rise Pty Ltd||--||--||6.52|
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.